158 related articles for article (PubMed ID: 17332281)
1. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.
Gery S; Komatsu N; Kawamata N; Miller CW; Desmond J; Virk RK; Marchevsky A; Mckenna R; Taguchi H; Koeffler HP
Clin Cancer Res; 2007 Mar; 13(5):1399-404. PubMed ID: 17332281
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
3. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells.
Gery S; Komatsu N; Baldjyan L; Yu A; Koo D; Koeffler HP
Mol Cell; 2006 May; 22(3):375-82. PubMed ID: 16678109
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the RUNX3 gene in lung cancer.
Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer.
Suzuki H; Ouchida M; Yamamoto H; Yano M; Toyooka S; Aoe M; Shimizu N; Date H; Shimizu K
Lung Cancer; 2008 Jan; 59(1):24-31. PubMed ID: 17854949
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer.
Fukui T; Kondo M; Ito G; Maeda O; Sato N; Yoshioka H; Yokoi K; Ueda Y; Shimokata K; Sekido Y
Oncogene; 2005 Sep; 24(41):6323-7. PubMed ID: 16007200
[TBL] [Abstract][Full Text] [Related]
7. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
8. Abnormal expression of period 1 (PER1) in endometrial carcinoma.
Yeh KT; Yang MY; Liu TC; Chen JC; Chan WL; Lin SF; Chang JG
J Pathol; 2005 May; 206(1):111-20. PubMed ID: 15809976
[TBL] [Abstract][Full Text] [Related]
9. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer.
Xinarianos G; McRonald FE; Risk JM; Bowers NL; Nikolaidis G; Field JK; Liloglou T
Hum Mol Genet; 2006 Jul; 15(13):2038-44. PubMed ID: 16698880
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.
Marsit CJ; Okpukpara C; Danaee H; Kelsey KT
Mol Carcinog; 2005 Oct; 44(2):146-50. PubMed ID: 16013053
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer.
Park JC; Chae YK; Son CH; Kim MS; Lee J; Ostrow K; Sidransky D; Hoque MO; Moon C
Biochem Biophys Res Commun; 2008 Jan; 365(2):221-6. PubMed ID: 17980147
[TBL] [Abstract][Full Text] [Related]
13. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
Hinshelwood RA; Huschtscha LI; Melki J; Stirzaker C; Abdipranoto A; Vissel B; Ravasi T; Wells CA; Hume DA; Reddel RR; Clark SJ
Cancer Res; 2007 Dec; 67(24):11517-27. PubMed ID: 18089780
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
[TBL] [Abstract][Full Text] [Related]
18. Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro.
Xu QY; Gao Y; Liu Y; Yang WZ; Xu XY
Chin Med J (Engl); 2008 Sep; 121(18):1830-7. PubMed ID: 19080366
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer.
Cinti C; Macaluso M; Giordano A
Oncogene; 2005 Sep; 24(38):5821-6. PubMed ID: 16044156
[TBL] [Abstract][Full Text] [Related]
20. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
